Form 4: United Therapeutics Director Awarded Stock Options

United Therapeutics Director Tommy G Thompson received an annual award of 3,650 stock options with an exercise price of $306.41.

Summary

• Tommy G Thompson, a Director at United Therapeutics Corp (UTHR), was granted 3,650 stock options.
• The options have an exercise price of $306.41 per share.
• This grant is identified as an annual non-employee director award.
• The options become exercisable on July 9, 2025, and expire on July 24, 2035.
• Following this transaction, Mr. Thompson directly beneficially owns 3,650 derivative securities.

Sentiment

Score: 7

Explanation: The filing reports a routine equity award to a director, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The award of stock options to Director Tommy G Thompson aligns his interests with those of shareholders, incentivizing long-term company performance.
• The options were granted at an exercise price of $306.41, reflecting the market value at the time of grant.

Negatives

• No specific negative aspects are indicated in this Form 4 filing, which primarily reports a routine equity award.

Risks

• This Form 4 filing does not contain information regarding specific company risks.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• This Form 4 filing does not include direct quotes or paraphrased statements from company management.

Industry Context

This Form 4 filing, reporting an individual director's equity award, does not provide information relevant to broader industry trends or competitor analysis.

Comparison to Industry Standards

• This Form 4 filing does not provide information for comparison to industry-specific benchmarks or competitor results.

Stakeholder Impact

• Shareholders: The award of stock options to a director aligns their interests with shareholder value creation.
• Employees, Customers, Suppliers, Creditors: No direct impact indicated by this specific filing.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing beyond the vesting and expiration of the options.

Key Dates

Keywords

United Therapeutics, UTHR, Stock Options, Director Compensation, SEC Form 4, Equity Award, Tommy G Thompson